PubMed HealthSearch

Biomedical subjects

H I Silverman

Publications and source records attributed to H I Silverman.

8 recordsLinked to original sources

Bioavailability and cardiovascular safety of Dexatrim (phenylpropanolamine hydrochloride) from a controlled-release caplet.

The bioavailability and pharmacokinetics of phenylpropanolamine hydrochloride (PPA HCl) from a Dexatrim controlled-release (CR) caplet and solution was studied. Each subject (n = 12) received either a 75 mg PPA HCl CR caplet once daily or a 25 mg PPA HCl solution given three times a day. All subjects received the medication for 4 consecutive days. On Day 1, the mean +/- SEM, AUC, tmax, and Cmax values were 1651 +/- 127 ng x h ml-1, 4.5 +/- 0.26 h and 143 +/- 13.5 ng ml-1, respectively, for the CR caplet and 1716 +/- 90.3 ng x h ml-1, 1.25 +/- 0.08 h and 126 +/- 5.8 ng ml-1 for the solution, respectively. At steady state (Day 4), the mean +/- SEM, AUC, tmax, and Cmax values were 1832 +/- 101 ng x h ml-1, 4.17 +/- 0.17 h and 151 +/- 6.5 ng ml-1, respectively, for the CR caplet and 2014 +/- 116 ng x h ml-1, 1.33 +/- 0.09 h and 143 +/- 8.7 ng ml-1, respectively, for the solution. The data from Day 1 were fitted to an oral one compartment model with a first order absorption rate constant, kA, first order elimination rate constant, k and lag time. The mean +/- SEM, kA, elimination half-life and lag time for PPA HCl from the CR caplet were 0.488 +/- 0.182 ng h ml-1, 5.84 +/- 1.66 h and 0.394 +/- 0.224 h, respectively. The mean +/- SEM, kA, elimination half-life and lag time for PPA HCl from the solution were 2.87 +/- 1.51 ng x h ml-1, 3.73 +/- 1.21 h, and 0.325 +/- 0.101 h, respectively. The smaller apparent kA and longer elimination half-life for PPA HCl from the CR caplet is due to the slow release of PPA HCl, thereby slowing its absorption producing sustained plasma drug concentrations. Blood pressures (supine and sitting) and heart rates measured at the time of blood sampling after the administration of the PPA HCl dosage forms demonstrated no clinically significant relationship between cardiovascular response and PPA HCl plasma concentration. These data demonstrate the bioavailability and pharmacokinetics of PPA HCl from a CR caplet and an immediate release solution.

Administration, Oral

A comparison of the effects of phenylpropanolamine, d-amphetamine and d-norpseudoephedrine on open-field locomotion and food intake in the rat.

d,l-Norephedrine (PPA) is available as an over-the-counter appetite suppressant and nasal decongestant in the U.S.A. The pseudoisomer d-norpseudoephedrine, is available as an appetite suppressant in Europe, and has been isolated as one of the stimulatory components (cathine) of the Khat plant. Some authors have misidentified cathine as PPA and this confusion in the literature has resulted. PPA and d-norpseudoephedrine possess significantly different pharmacological properties despite having identical structural formulae. Anorectic activity was determined in a food-deprived rat model. PPA and d-norpseudoephedrine were approximately one-tenth as potent as d-amphetamine with all compounds producing a dose-dependent decrease in food intake. Locomotor activity in an open-field apparatus was determined as an index of CNS stimulation. Male Sprague-Dawley rats treated with d-norpseudoephedrine, in doses between 10 and 50 mg/kg, exhibited significantly increased locomotor scores compared to saline (control) treated animals, an increase similar to that caused by 2 mg/kg d-amphetamine. PPA (5-50 mg/kg) failed to increase locomotion significantly. These results indicate that although each compound tested decreased food intake in a dose-dependent fashion, significant differences in open-field locomotion do exist between PPA, d-norpseudoephedrine, and d-amphetamine. Stereoisomeric compounds, although structurally similar, frequently have different pharmacological effects. Thus extreme care must be taken to properly identify these compounds in the literature.

Animals

Adverse effects of commonly used systemic drugs on the human eye. Part III.

Four tables are presented listing the adverse effects of commonly used drugs on the human eye. Both brand names and generic names of drugs are used. The optometrist using the tables can look up either the drug (to find the adverse effects) or the symptom (to find the drugs that might cause it).

Drug-Related Side Effects and Adverse Reactions